Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2026)
Bicycle Therapeutics (BCYC) posted Net Cash Flow of -$66.7 million for Q1 2026, down 234.55% on a QoQ basis from -$19.9 million in Q4 2025, and up 23.36% year-over-year from -$54.1 million in Q1 2025.
Bicycle Therapeutics (BCYC) Net Cash Flow (2018 - 2026) Analysis & Trends
Bicycle Therapeutics' Net Cash Flow history runs 9 years deep, the most recent figure standing at -$66.7 million for Q1 2026.
- Quarterly Net Cash Flow rose 23.36% year-over-year to -$66.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$231.8 million (down 169.04% YoY) and the FY2025 annual result came in at -$252.2 million, down 171.27% from the prior year.
- Net Cash Flow was -$66.7 million for Q1 2026 at Bicycle Therapeutics, down from -$19.9 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $504.6 million in Q2 2024 and bottomed at -$87.0 million in Q1 2025.
- A 5-year average of $7.2 million and a median of -$33.1 million in 2022 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2022 — Net Cash Flow tumbled 1200.46% — and 2023, when it surged 2780.59%.
- Bicycle Therapeutics' Net Cash Flow stood at -$25.9 million in 2022, then plunged by 81.5% to -$47.0 million in 2023, then jumped by 79.64% to -$9.6 million in 2024, then slumped by 108.5% to -$19.9 million in 2025, then plunged by 234.55% to -$66.7 million in 2026.
- Business Quant data shows BCYC's Net Cash Flow at -$66.7 million in Q1 2026, -$19.9 million in Q4 2025, and -$71.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Bicycle Therapeutics | 289.88 Mn | 289.88 Mn | - | -66.69 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -66.69 Mn |
| Mar 31, 2026 | -66.69 Mn |
| Dec 31, 2025 | -19.94 Mn |
| Dec 31, 2025 | -19.94 Mn |
| Sep 30, 2025 | -71.88 Mn |
| Sep 30, 2025 | -71.88 Mn |
| Jun 30, 2025 | -73.33 Mn |
| Jun 30, 2025 | -73.33 Mn |
| Mar 31, 2025 | -87.02 Mn |
| Mar 31, 2025 | -87.02 Mn |
| Dec 31, 2024 | -9.56 Mn |
| Dec 31, 2024 | -9.56 Mn |
| Sep 30, 2024 | -72.20 Mn |
| Sep 30, 2024 | -72.20 Mn |
| Jun 30, 2024 | 504.56 Mn |
| Jun 30, 2024 | 504.56 Mn |
| Mar 31, 2024 | -69.01 Mn |
| Mar 31, 2024 | -69.01 Mn |
| Dec 31, 2023 | -46.95 Mn |
| Dec 31, 2023 | -46.95 Mn |